Tert-butyl 4-(3,4-dihydroisoquinolin-5-yl)piperazine-1-carboxylate → Tert-butyl 4-(3,4-dihydroisoquinolin-5-yl)-3-oxopiperazine-1-carboxylate
Reaction equation
[CH:1]1[C:10]2[C:5](=[C:6]([N:11]3[CH2:16][CH2:15][N:14]([C:17]([O:19][C:20]([CH3:23])([CH3:22])[CH3:21])=[O:18])[CH2:13][C:12]3=[O:24])[CH:7]=[CH:8][CH:9]=2)[CH:4]=[CH:3][N:2]=1.C1C2C(=C(N3CCN(C(OC(C)(C)C)=O)CC3)C=CC=2)CCN=1>>[CH:1]1[C:10]2[C:5](=[C:6]([N:11]3[CH2:16][CH2:15][N:14]([C:17]([O:19][C:20]([CH3:22])([CH3:21])[CH3:23])=[O:18])[CH2:13][C:12]3=[O:24])[CH:7]=[CH:8][CH:9]=2)[CH2:4][CH2:3][N:2]=1Participants
3
Procedure
Intermediate 21 was prepared from Intermediate 21A as described for Intermediate 18. MS (ESI) m/z: 330.1 (M+H)+.
Sources & evidence
- ORD record
- ord-8e45734c6b3d487cb5862e0668536642
- Source dataset
- uspto-grants-2015_11
- Patent number
- US09192607B2
Reaction notes
Loading…